Care Capital Investments III L.P.
CIK 1599355 · last filed 2015-05-12
Care Capital Investments III L.P. is a corporate insider who has filed 5 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for CLCD, was dated May 12, 2015. Across all open-market trades the lifetime net is +$4.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $552.8K across reported positions. The firm reports its address in Princeton, NJ. 19 SEC filings were submitted jointly with Care Capital III LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NERV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PRINCETON, NJ 08542
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 1,520,136 | — | — | $0 | 1 | 2015-05-12 |
| NERV | 10%+ Owner | 207,824 | $2.66 | $552.8K | -$4.98M | 3 | 2015-03-20 |
| NephroGenex, Inc. (NRX) Delisted | Director | 3,038,505 | — | — | $9.48M | 1 | 2014-02-19 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-12 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Conv (C) | +1,545,539 | $0 | EDGAR |
| 2015-03-20 | NERV | Sell (S) | −1,206,700 | -$6.94M | EDGAR |
| 2015-01-26 | NERV | Sell (S) | −482,112 | -$2.46M | EDGAR |
| 2014-07-09 | NERV | Mixed | +913,501 | $5.48M | EDGAR |
| 2014-02-19 | NephroGenex, Inc. (NRX) Delisted | Mixed | +4,241,097 | $9.48M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.